Evidence map›Paper›PMID 41727322›Full record

ReviewFrontiers in cell and developmental biology2026

WWC proteins as emerging biomarkers and therapeutic targets in cancer pathogenesis.

Shuge Wang, Junzhe Li, Xianhua Xu, Shijie Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuge Wang *Department of Pathology, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan, China.
Junzhe Li *Department of Thoracic Surgery, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan, China.
Xianhua XuDepartment of Pathology, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan, China.
Shijie XuMedical Research Center, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WW and C2 domain-containing (WWC) proteins have emerged as pivotal regulators of cancer initiation, progression, and therapeutic resistance. This review synthesizes current evidence demonstrating that WWC1, WWC2, and WWC3 exert context-dependent effects across malignancies, with WWC2 consistently functioning as a tumor suppressor while WWC1 and WWC3 display tissue-specific variability. By integrating and regulating multiple signaling pathways, particularly Hippo and Wnt, WWC proteins function as molecular scaffolds that regulate proliferation, apoptosis, epithelial-mesenchymal transition, and metastasis. This review provides a comprehensive overview of the molecular characteristics, biological functions, and clinical implications of WWC proteins, highlighting their potential as prognostic biomarkers and therapeutic targets for precision oncology.

Indexed as

cancerHippo pathwaytherapeutic targetsWnt/β-catenin pathwayWWC

Identifiers

PMID41727322
PMCPMC12916667

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.